Bone Biologics Expands Relationship with UCLA

Bone Biologics (BB) entered into an exclusive license agreement with UCLA for global application of NELL-1 protein in the treatment of osteoporosis and trauma, through a technology transfer. NELL-1 is a recombinant human protein growth factor that supports normal bone development. Researchers are examining its ability to systemically...

document icon

You are out of free articles for this month

Subscribe as a Guest for $0 and unlock a total of 5 articles per month.

You are out of five articles for this month

Subscribe as an Executive Member for access to unlimited articles, THE ORTHOPAEDIC INDUSTRY ANNUAL REPORT and more.


Julie Vetalice is ORTHOWORLD's Editorial Assistant. She has covered the orthopedic industry for over 20 years, having joined the company in 1999.

Contact Us